. 2023 Feb 21;12(5):1734. doi: 10.3390/jcm12051734

Table 4.

Results of upadacitinib on key patient-reported outcomes in the SELECT trial program.

Study	Outcome ^a	Week	Placebo	MTX	ABA	ADA	Upa 15 mg	Upa 30 mg
NEXT [21]	ΔVAS Pain	12	−10.3				−29.9 ^‡	−31.7 ^‡
	ΔFACIT-F	12	3.0				7.9 ^‡	7.7 ^‡
	ΔSF36-PCS	12	3.0				7.6 ^‡	8.0 ^‡
	ΔHAQ-DI	12	−0.26				−0.61 ^‡	−0.55 ^‡
BEYOND [22]	ΔSF36-PCS	12	2.4				5.8 ^‡	7.0 ^‡
	ΔSF36-PCS	24	NA				7.2	8.0
	ΔHAQ-DI	12	−0.16				−0.41 ^‡	−0.44 ^‡
COMPARE [23]	ΔVAS Pain	12	−15.7			−25.6	−32.1 ^†,¶
	ΔFACIT-F	12	4.8			7.4	9.0 ^†,ǀ
	ΔFACIT-F	26	5.5			8.2	9.7 ^†,ǀ
	ΔSF36-PCS	12	3.6			6.3	7.9 ^†,ǁ
	ΔSF36-PCS	26	4.5			7.8	9.5 ^†,ǁ
	ΔHAQ-DI	12	−0.28			−0.49	−0.60 ^†,ǁ
CHOICE [24]	ΔFACIT-F	12			8.35		9.61
	ΔFACIT-F	24			10.32		10.73
	ΔSF36-PCS	12			7.03		9.62
	ΔSF36-PCS	24			9.40		10.97
MONOTHERAPY [25]	ΔVAS Pain	14		−13.88			−26.15 ^¶¶	−33.18 ^¶¶
	ΔSF36-PCS	14		4.3			8.3 ^¶	10.2 ^¶
	ΔHAQ-DI	14		−0.32			−0.65 ^¶	−0.73 ^¶
EARLY [26]	ΔVAS Pain	12		−25.36			−36.28 ^¶	−39.67 ^¶
	ΔVAS Pain	24		−28.40			−39.84 ^¶	−44.67 ^¶
	ΔFACIT-F	12		6.80			10.01 ^¶	9.57 ^¶
	ΔFACIT-F	24		7.37			10.59 ^¶	10.56 ^¶
	ΔSF36-PCS	12		5.77			10.09 ^¶	10.11 ^¶
	ΔSF36-PCS	24		6.99			10.97 ^¶	11.69 ^¶
	ΔHAQ-DI	12		−0.49			−0.83 ^¶	−0.86 ^¶
	ΔHAQ-DI	24		−0.60			−0.87 ^¶	−0.91 ^¶

^a Minimum clinically important differences: VAS pain, ≥10 mm; FACIT-T, ≥4 points; SF36-PCS, ≥2.5 points; HAD-DI, ≥0.22 units. ADA—adalimumab; ABA—abatacept; ∆—mean change from baseline; FACIT-F—functional assessment of chronic illness therapy fatigue scale; HAQ-DI—health assessment questionnaire disability index; MTX—methotrexate; SF-36 PCS—36-item short form health survey physical component summary score; VAS—visual analog scale. ^† 0.001 upadacitinib versus placebo. ^‡ 0.0001 upadacitinib versus placebo. ^ǀ 0.05 upadacitinib versus active comparator (adalimumab, abatacept, methotrexate). ^ǁ 0.01 upadacitinib versus active comparator. ^¶ 0.001 upadacitinib versus active comparator. ^¶¶ 0.0001 upadacitinib versus active comparator.